SHPG has been the topic of several other reports. Goldman Sachs Group Inc. restated a buy rating on shares of Shire PLC in a report on Tuesday, June 28th. HSBC downgraded Shire PLC from a buy rating to a hold rating in a research report on Monday, September 26th. JPMorgan Chase & Co. reaffirmed an overweight rating on shares of Shire PLC in a research report on Monday, October 3rd. Piper Jaffray Cos. set a $201.00 target price on Shire PLC and gave the company a hold rating in a research report on Saturday, October 1st. Finally, Leerink Swann reaffirmed a buy rating and issued a $213.00 target price (down from $225.00) on shares of Shire PLC in a research report on Thursday, June 16th. Five investment analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $232.75.
Shire PLC (NASDAQ:SHPG) opened at 194.50 on Friday. The stock has a market cap of $57.93 billion, a P/E ratio of 40.42 and a beta of 1.16. The stock has a 50 day moving average of $195.56 and a 200 day moving average of $187.04. Shire PLC has a 12-month low of $147.60 and a 12-month high of $231.32.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.35. The firm had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. Shire PLC’s revenue was up 55.9% on a year-over-year basis. During the same period in the previous year, the firm earned $2.63 EPS. On average, equities research analysts anticipate that Shire PLC will post $12.92 earnings per share for the current fiscal year.
The company also recently disclosed a dividend, which was paid on Friday, October 7th. Shareholders of record on Friday, September 9th were paid a $0.139 dividend. The ex-dividend date was Wednesday, September 7th. Shire PLC’s dividend payout ratio is currently 15.63%.
Large investors have recently modified their holdings of the stock. Jennison Associates LLC boosted its stake in shares of Shire PLC by 13.2% in the second quarter. Jennison Associates LLC now owns 8,294,030 shares of the biopharmaceutical company’s stock worth $1,526,765,000 after buying an additional 968,101 shares in the last quarter. FMR LLC boosted its stake in shares of Shire PLC by 86.7% in the second quarter. FMR LLC now owns 2,663,506 shares of the biopharmaceutical company’s stock worth $490,297,000 after buying an additional 1,237,100 shares in the last quarter. Lone Pine Capital LLC purchased a new stake in shares of Shire PLC during the second quarter worth $465,566,000. Capital World Investors purchased a new stake in shares of Shire PLC during the second quarter worth $285,568,000. Finally, Vanguard Group Inc. purchased a new stake in shares of Shire PLC during the second quarter worth $278,421,000. Institutional investors own 24.26% of the company’s stock.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.